News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


Two new treatments funded for blood disorders and cancers

Media release

Two new treatments funded for blood disorders and cancers

20 August, 2014

Up to 400 patients a year are likely to live longer as a result of PHARMAC funding two new medicines.

The medicines are azacitidine (Vidaza) and lenalidomide (Revlimid), which will be funded from 1 September.

Azacitidine is being funded for a group of blood disorders collectively known as myelodysplastic syndromes (MDS), and for two types of leukaemia (chronic myelomonocytic leukaemia and
MDS-associated acute myeloid leukaemia).

Lenalidomide will be funded for multiple myeloma, a type of blood cancer. It will be an alternative to the currently funded treatments bortezomib and thalidomide, and funded for use in patients
if these treatments fail.

Director of Operations Sarah Fitt says both new medicines have proven effectiveness and should lead to patients living longer. They are important additions to the tools that haematologists will
have to treat multiple myeloma, leukaemia and MDS.

“Clinical trials of azacitidine showed it nearly doubles the survival rate of people with MDS, compared to conventional treatment,” she says. “This is a significant improvement for this patient group,
who have had limited treatment options.

“In the case of lenalidomide, the aim of treatment is to delay disease progression and also to prolong life. The trials show that lenalidomide is effective in patients whose disease has progressed
after receiving previous treatments.”

Sarah Fitt says another benefit of lenalidomide is that it doesn’t have some of the side effects of the other funded treatments, which can be debilitating for patients. Bortezomib and thalidomide can
cause peripheral neuropathy, a condition that causes tingling, numbness and pain in hands and feet.

“So, as well as being an effective treatment, lenalidomide is less likely to cause debilitating peripheral neuropathy than the currently available treatments, so it may be a better treatment option for
some patients.”


© Scoop Media

Culture Headlines | Health Headlines | Education Headlines


Howard Davis: Review - A Girl Named Mo

Moana Ete brought her three-piece band A Girl Named Mo to Wellington's intimate and iconic Bats Theatre last week for a five-night residency. Each show was recorded and filmed live for the release of her debut album 'Platonic/Romantic' on Loop records later this year. More>>

For The Birds: Who Will Be Crowned Bird Of The Year?

The competition involves well-known and enthusiastic New Zealanders acting as ‘campaign managers’ for their favourite birds with many going to great lengths to get New Zealanders to vote for their chosen bird... More>>


  • Image Out-Link - Giselle Clarkson on Twitter
  • Gordon Campbell: On Bob Dylan's Nobel (And The Surplus)

    So Bob Dylan has just won the Nobel Prize for… Literature? Wow. I’d be just as happy if he’d won for his work on particle physics (“One Grain of Sand”, “Simple Twist of Fate”) or got the Economics prize for his work on the theory of contracting (“Don’t Think Twice Its Alright”) ... More>>


    Scoop Review Of Books: Whose Goat Was That?

    Mysterious Mysteries of Aro Valley is a sharp, satirical and sometimes downright scary romp through and around that valley in ways that made me question the realities of the places I thought I knew so well. More>>


    NZ On Air TV Funding: More Comedy Comes Out Of The Shadows

    Paranormal Event Response Unit is a series conceived by Jemaine Clement and Taika Waititi as a TV spin-off from their highly acclaimed feature film What We Do In The Shadows. More>>


    Mars News: Winners Announced For The 2016 Apra Silver Scroll Awards

    Wellington singer-songwriter and internationally acclaimed musician Thomas Oliver has won the 2016 APRA Silver Scroll Award with his captivating love song ‘If I Move To Mars’. More>>


    Get More From Scoop



    Search Scoop  
    Powered by Vodafone
    NZ independent news